288 related articles for article (PubMed ID: 38667744)
1. Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies.
Omari M; Alkhalil M
J Cardiovasc Dev Dis; 2024 Apr; 11(4):. PubMed ID: 38667744
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
Nurmohamed NS; Ditmarsch M; Kastelein JJP
Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
[TBL] [Abstract][Full Text] [Related]
4. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
5. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
6. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
Kim K; Ginsberg HN; Choi SH
Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
[TBL] [Abstract][Full Text] [Related]
7. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Chapman MJ; Le Goff W; Guerin M; Kontush A
Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
11. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
[TBL] [Abstract][Full Text] [Related]
12. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
13. Emerging lipid lowering agents targeting LDL cholesterol.
Wójcik C
Postgrad Med; 2020 Jun; 132(5):433-440. PubMed ID: 32243228
[TBL] [Abstract][Full Text] [Related]
14. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
Nishikido T; Ray KK
Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
[TBL] [Abstract][Full Text] [Related]
15. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
Hoogeveen RC; Ballantyne CM
Clin Chem; 2021 Jan; 67(1):143-153. PubMed ID: 33257928
[TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
17. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
Zhou R; Stouffer GA; Smith SC
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):533-549. PubMed ID: 34138676
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.
Nelson AJ; Sniderman AD; Ditmarsch M; Dicklin MR; Nicholls SJ; Davidson MH; Kastelein JJP
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
